First human trial launches for promising new cancer pill targeting multiple tumors

NCT ID NCT06257264

Recruiting now Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study testing a new oral drug called BG-68501 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with other cancer medications for specific breast cancers. Researchers will also get an early look at whether the treatment helps shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Auckland City Hospital
RECRUITING

Auckland, 1023, New Zealand
Avera Cancer Institute
RECRUITING

Sioux Falls, South Dakota, 57105-2108, United States
Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Blacktown Cancer and Haematology Centre
RECRUITING

Blacktown, New South Wales, NSW 2148, Australia
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Cancer Research South Australia
RECRUITING

Adelaide, South Australia, SA 5000, Australia
Florida Cancer Specialists and Research Institute
COMPLETED

Lake Mary, Florida, 32746-2115, United States
Genesiscare North Shore
RECRUITING

St Leonards, New South Wales, NSW 2065, Australia
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150000, China
Hoag Memorial Presbyterian
RECRUITING

Newport Beach, California, 92663-4162, United States
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410013, China
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Monash Health
RECRUITING

Clayton, Victoria, VIC 3168, Australia
Nepean Hospital
RECRUITING

Kingswood, New South Wales, NSW 2747, Australia
Princess Alexandra Hospital
RECRUITING

Woolloongabba, Queensland, QLD 4102, Australia
Rambam Health Care Center
RECRUITING

Haifa, 3109601, Israel
Saint Vincents Hospital Sydney
RECRUITING

Darlinghurst, New South Wales, NSW 2010, Australia
Shaare Zedek Medical Center
RECRUITING

Jerusalem, 9103102, Israel
Shengjing Hospital Affiliated of China Medical University
RECRUITING

Shenyang, Liaoning, 110022, China
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
RECRUITING

Guangzhou, Guangdong, 510245, China
The First Affiliated Hospital of Xian Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710061, China
The Institute of Oncology, Arensia Exploratory Medicine
RECRUITING

Chisinau, 2025, Moldova
Titan Health Partners Llc Dba Astera Cancer Care
RECRUITING

East Brunswick, New Jersey, 08816-4096, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110-1010, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR BLADDER CANCER BREAST CANCER ENDOMETRIAL CANCER GASTRIC CANCER GASTROESOPHAGEAL CANCER HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER HORMONE RECEPTOR-POSITIVE BREAST CANCER OVARIAN CANCER PROSTATE CANCER SMALL CELL LUNG CANCER TNBC, TRIPLE NEGATIVE BREAST CANCER